Predictive value of serum CCL18 for recurrence and invasiveness in pituitary neuroendocrine tumors

Key Points

• Serum CCL18 is a promising biomarker for predicting tumor behavior and patient outcomes.
• Higher CCL18 levels correlate with increased rates of tumor recurrence and invasiveness.
• Observational analysis examines data from patients with diagnosed pituitary neuroendocrine tumors.
• Findings may enable earlier interventions based on CCL18 levels, improving treatment efficiency.